The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Selective degradation of CDK6 by a palbociclib based PROTAC
Open accessAbstract
Development of selective kinase inhibitors that target the ATP binding site continues to be a challenge largely due to similar binding pockets. Palbociclib is a cyclin-dependent kinase inhibitor that targets the ATP binding site of CDK4 and CDK6 with similar potency. The enzymatic function associated with the kinase can be effectively probed using kinase inhibitors however the kinase-independent functions cannot. Herein, we report a palbociclib based PROTAC that selectively degrades CDK6 while sparing the homolog CDK4. We used competition studies to characterize the binding and mechanism of CDK6 degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas multiple studies have described numerous CRBN-recruiting dual-selective degraders and CDK6-selective degraders 70–73, none report CDK4-selective degraders; the only reported CDK4-selective degraders are built on a slightly different warhead, ribociclib 74.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Yang, C., Li, Z., Bhatt, T., Dickler, M. N., Giri, D. D., Scaltriti, M., Baselga, J. M., Rosen, N. X., & Chandarlapaty, S. (2016) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 420
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413
Zhou, B. N., Hu, J., Xu, F., Chen, Z., Bai, L., Fernández‐Salas, E., Lin, M., Liu, L., Yang, C., Zhao, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 376
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611281 · Cited by 293
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 223
Self-citationWurz, R. P., Dellamaggiore, K., Dou, H., Javier, N., LO, M. M. ‐., McCarter, J. D., Mohl, D. A., Sastri, C. E., Lipford, J. R., & Cee, V. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01781 · Cited by 218
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Saenz, D. T., Fiskus, W. C., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P. A., Shen, A., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2016.393 · Cited by 187
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Sonawane, Y. A., Taylor, M., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00150 · Cited by 164
Self-citationPROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer
Zhao, B., & Burgess, K. (2019) · Chemical Communications · doi:10.1039/c9cc00163h · Cited by 130
Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition
Lü, H., & Schulze‐Gahmen, U. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600388 · Cited by 104
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation
Bellan, C., Falco, G. D., Lazzi, S., Micheli, P., Vicidomini, S., Schürfeld, K., Amato, T., Palumbo, A., Bagella, L., Sabattini, E., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1588 · Cited by 61
Falco, G. D., Bellan, C., D’Amuri, A., Angeloni, G., Leucci, E., Giordano, A., & Leoncini, L. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1497 · Cited by 50
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
Robb, C. M., Kour, S., Contreras, J. I., Agarwal, E., Barger, C. J., Rana, S., Sonawane, Y. A., Neilsen, B. K., Taylor, M., Kizhake, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23749 · Cited by 41
Self-citationSimone, C., & Giordano, A. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402008 · Cited by 29
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy
Rana, S., Sonawane, Y. A., Taylor, M., Kizhake, S., Zahid, M., & Natarajan, A. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.020 · Cited by 22
Self-citationContreras, J. I., Robb, C. M., King, H. M., Baxter, J., Crawford, A. J., Kour, S., Kizhake, S., Sonawane, Y. A., Rana, S., Hollingsworth, M. A., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00077 · Cited by 10
Self-citation
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Zhou, 2017, Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression, J Med Chem
Cited by
Sorted by citations
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 587
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 565
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220965528 · Cited by 404
Metadata
- Authors
- Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A.
- Affiliations
- University of Nebraska Medical Center (US)
- Fred and Pamela Buffett Cancer Center (US)
- Corresponding author
- Rana, Sandeep
- Natarajan, Amarnath
- ORCID
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 29
- Issue
- 11
- Pages
- 1375-1379
- ISSN
- 0960-894X (ISSN-L)
- PMC
- PMC6487213
- OpenAlex
- W2924113881
- Cited by
- 135
- References
- 29
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 13 · 2023: 13 · 2022: 20 · 2021: 25 · 2020: 31 · 2019: 4
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Bioorganic & Medicinal Chemistry Letters (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA197999, P30CA036727)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- palbociclib, PROTACs, CDK4, kinase-independent function, selective protein degradation, ATP binding site, kinase inhibitors, competitive binding
- MeSH terms
- Dose-Response Relationship, Drug, Humans, Models, Molecular, Piperazines, Pyridines, Structure-Activity Relationship, Molecular Structure, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 6, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
